1425045-01-7

Basic information

• Product Name: 1,3-diMethyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one
• Synonyms: 1,3-diMethyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one
• CAS NO: 1425045-01-7
• Molecular Formula: C13H20BNO3
• Molecular Weight: 249.118
• Mol File: 1425045-01-7.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: 1,3-diMethyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-diMethyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one(1425045-01-7)
• EPA Substance Registry System: 1,3-diMethyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one(1425045-01-7)

Safety Data

• Hazardous Substances Data: 1425045-01-7(Hazardous Substances Data)

Usage

Description

1,3-diMethyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one is a chemical compound with the molecular formula C15H24BNO2. It is a derivative of pyridin-2(1H)-one, and it contains a boron atom. 1,3-diMethyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one is known for its ability to form stable boron-containing complexes and is utilized in the development of boronic acid-based compounds for pharmaceutical and medical applications. The presence of the boron atom in this compound makes it valuable for its unique chemical properties and potential applications in diverse fields.

Uses

Used in Organic Synthesis:
1,3-diMethyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one is used as a reagent or catalyst in organic synthesis for various chemical reactions. Its unique chemical properties and ability to form stable boron-containing complexes make it a valuable component in the synthesis of complex organic molecules.
Used in Pharmaceutical and Medical Applications:
1,3-diMethyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one is used as a precursor in the development of boronic acid-based compounds for pharmaceutical and medical applications. Its unique chemical properties and potential applications in diverse fields make it a promising candidate for the development of new drugs and therapies.
Used in Research and Development:
1,3-diMethyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one is used in research and development for exploring its potential applications in various fields. Its unique chemical properties and ability to form stable boron-containing complexes make it an interesting subject for further study and development.

Upstream product

• 1083168-83-5 2-methoxy-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 
• 74-88-4 methyl iodide 
• 73183-34-3 bis(pinacol)diborane 
• 89488-30-2 5-bromo-2-hydroxy-3-methyl pyridine 
• 6456-92-4 1,3-dimethylpyridin-2(1H)-one 
• 51417-13-1 5-bromo-1,3-dimethyl-1,2-dihydropyridin-2-one 

Downstream Products

• 1610374-12-3 5-(5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)-1,3-dimethylpyridin-2(1H)-one 
• 1610373-91-5 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea 

Relevant articles and documents

Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor

Components of the chromatin remodelling switch/sucrose nonfermentable (SWI/SNF) complex are recurrently mutated in tumors, suggesting that altering the activity of the complex plays a role in oncogenesis. However, the role that the individual subunits play in this process is not clear. We set out to develop an inhibitor compound targeting the bromodomain of BRD9 in order to evaluate its function within the SWI/SNF complex. Here, we present the discovery and development of a potent and selective BRD9 bromodomain inhibitor series based on a new pyridinone-like scaffold. Crystallographic information on the inhibitors bound to BRD9 guided their development with respect to potency for BRD9 and selectivity against BRD4. These compounds modulate BRD9 bromodomain cellular function and display antitumor activity in an AML xenograft model. Two chemical probes, BI-7273 (1) and BI-9564 (2), were identified that should prove to be useful in further exploring BRD9 bromodomain biology in both in vitro and in vivo settings.

BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE

The disclosure provides BRD9 bifunctional compounds of Formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, to their preparation, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases and disorders mediated by a bromodomain-containing protein, such as bromodoma in-containing protein 9 (BRD9)

COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION

The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.